Shire and AbbVie separately set out new financial targets to investors following U.K.-listed Shire's rejection of $46 billion takeover advance from its U.S. rival.
from WSJ.com: US Business http://ift.tt/1ipCOI8
via IFTTT
from WSJ.com: US Business http://ift.tt/1ipCOI8
via IFTTT
No comments:
Post a Comment